DDInter923 DDInter255
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Busulfan
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Etonogestrel {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Busulfan
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Procainamide
Procainamide {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Busulfan
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) upregulates {v} (Gene) GPER1
GPER1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) downregulates {v} (Gene) MCM2
MCM2 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amiodarone
Amiodarone {u} (Compound) upregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) downregulates {v} (Gene) TXNRD1
TXNRD1 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} (Compound) binds {v} (Gene) EPHA3
EPHA3 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) ABL1
ABL1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Melphalan
Melphalan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Busulfan (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Busulfan (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Procainamide and Procainamide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Busulfan (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) upregulates GPER1 (Gene) and GPER1 (Gene) is upregulated by Busulfan (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) downregulates MCM2 (Gene) and MCM2 (Gene) is upregulated by Busulfan (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) upregulates ACAT2 (Gene) and ACAT2 (Gene) is downregulated by Busulfan (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) downregulates TXNRD1 (Gene) and TXNRD1 (Gene) is downregulated by Busulfan (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib (Compound) binds EPHA3 (Gene) and EPHA3 (Gene) is upregulated by Busulfan (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib (Compound) binds ABL1 (Gene) and Crizotinib (Compound) upregulates ABL1 (Gene) and ABL1 (Gene) is upregulated by Busulfan (Compound)
Infliximab may lead to a major life threatening interaction when taken with Melphalan and Melphalan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)